Ono Pharmaceutical Co., Ltd. (TYO:4528)
Japan · Delayed Price · Currency is JPY 2,420.50
-21.00 (-0.86%)
May 19, 2026, 9:54 AM JST
Ono Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 515,785 | 486,871 | 502,672 | 447,187 | 361,361 | |
Revenue Growth (YoY) | 5.94% | -3.14% | 12.41% | 23.75% | 16.84% |
Cost of Revenue | 141,716 | 147,950 | 127,126 | 110,062 | 93,511 |
Gross Profit | 374,069 | 338,921 | 375,546 | 337,125 | 267,850 |
Selling, General & Admin | 123,691 | 122,219 | 97,389 | 86,643 | 74,119 |
Research & Development | 147,043 | 149,866 | 112,174 | 95,344 | 75,879 |
Other Operating Expenses | 11,099 | 1,592 | 2,807 | 2,250 | 4,099 |
Operating Expenses | 281,833 | 277,129 | 215,251 | 187,080 | 157,035 |
Operating Income | 92,236 | 61,792 | 160,295 | 150,045 | 110,815 |
Interest Expense | -3,539 | -1,450 | -125 | -89 | -84 |
Interest & Investment Income | 3,956 | 4,631 | 3,574 | 2,403 | 2,349 |
Earnings From Equity Investments | - | 125 | 1 | 4 | -6 |
Currency Exchange Gain (Loss) | - | -1,861 | 347 | -723 | -425 |
Other Non Operating Income (Expenses) | 1 | 21 | 235 | 182 | 399 |
EBT Excluding Unusual Items | 92,654 | 63,258 | 164,327 | 151,822 | 113,048 |
Gain (Loss) on Sale of Investments | - | -1,730 | -92 | -46 | -116 |
Gain (Loss) on Sale of Assets | - | -214 | -118 | -94 | -64 |
Asset Writedown | - | -1,981 | -51 | -498 | -316 |
Legal Settlements | - | -4 | -333 | -7,652 | -7,527 |
Pretax Income | 92,654 | 59,329 | 163,733 | 143,532 | 105,025 |
Income Tax Expense | 22,743 | 9,163 | 35,694 | 30,619 | 24,340 |
Earnings From Continuing Operations | 69,911 | 50,166 | 128,039 | 112,913 | 80,685 |
Minority Interest in Earnings | -144 | -119 | -62 | -190 | -166 |
Net Income | 69,767 | 50,047 | 127,977 | 112,723 | 80,519 |
Net Income to Common | 69,767 | 50,047 | 127,977 | 112,723 | 80,519 |
Net Income Growth | 39.40% | -60.89% | 13.53% | 40.00% | 6.75% |
Shares Outstanding (Basic) | 470 | 470 | 480 | 488 | 496 |
Shares Outstanding (Diluted) | 470 | 470 | 480 | 488 | 497 |
Shares Change (YoY) | 0.07% | -2.14% | -1.70% | -1.65% | -0.54% |
EPS (Basic) | 148.49 | 106.55 | 266.61 | 230.85 | 162.19 |
EPS (Diluted) | 148.41 | 106.41 | 266.57 | 230.79 | 162.16 |
EPS Growth | 39.47% | -60.08% | 15.50% | 42.32% | 7.33% |
Free Cash Flow | 130,797 | 77,028 | 106,640 | 154,270 | 56,332 |
Free Cash Flow Per Share | 278.23 | 163.97 | 222.15 | 315.90 | 113.45 |
Dividend Per Share | - | 80.000 | 80.000 | 70.000 | 56.000 |
Dividend Growth | - | - | 14.29% | 25.00% | 12.00% |
Gross Margin | 72.52% | 69.61% | 74.71% | 75.39% | 74.12% |
Operating Margin | 17.88% | 12.69% | 31.89% | 33.55% | 30.67% |
Profit Margin | 13.53% | 10.28% | 25.46% | 25.21% | 22.28% |
Free Cash Flow Margin | 25.36% | 15.82% | 21.21% | 34.50% | 15.59% |
EBITDA | 129,988 | 88,686 | 178,435 | 167,496 | 128,536 |
EBITDA Margin | 25.20% | 18.22% | 35.50% | 37.45% | 35.57% |
D&A For EBITDA | 37,752 | 26,894 | 18,140 | 17,451 | 17,721 |
EBIT | 92,236 | 61,792 | 160,295 | 150,045 | 110,815 |
EBIT Margin | 17.88% | 12.69% | 31.89% | 33.55% | 30.67% |
Effective Tax Rate | 24.55% | 15.44% | 21.80% | 21.33% | 23.18% |
Advertising Expenses | - | 30,651 | 24,019 | 17,837 | 11,496 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.